8月25日下午，益丰药房发布公告称，公司近日收到公司副总裁章佳的书面辞职报告。章佳因个人原因 申请辞去公司副总裁职务，辞职后不再担任公司其他任何职务。据悉，章佳于2024年6月25日期担任益 丰药房副总裁一职，原定任期到期日2027年6月24日。2024年年报显示，章佳2024年年末持有16.80万 股，2024年从公司获得的税前报酬为159.26万元。 2025年一季度，益丰药房新增门店94家，其中，自建门店26家，加盟店68家。另，关闭门店84家。截至 2025年一季度期末，公司门店总数1.47万家（含加盟店3880家），较上期末净增门店10家。 章佳于1981年11月出生，曾任沃尔玛中国采购部价格经理，屈臣氏中国采购部总监、护肤品采购负责 人，有生品见（南京）有限公司CMO，广州哆啦科技有限公司(fordeal)供应链副总裁，益丰药房副总 裁。 益丰药房主要经营模式包括商品采购、物流配送、仓储管理和门店销售等业务流程。2025年一季度，益 丰药房实现营收60.09亿元，同比增长0.64%；实现归母净利润4.49亿元，同比增长10.51%。 ...

（文章来源：证券日报） 证券日报网讯 8月25日晚间，益丰药房发布公告称，公司于2025年8月25日召开职工代表大会，经职工 代表大会审议通过，选举高佑成先生为公司职工代表董事，任期自本次职工代表大会通过之日起至公司 第五届董事会任期届满之日止。 ...

关于选举职工代表董事的公告 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《公司法》《上市公司章程指引》等法律法规、规范性文件及《公司 章程》的相关规定，为完善公司治理结构，益丰大药房连锁股份有限公司（以 下简称"公司"或"本公司"）于 2025 年 8 月 25 日召开职工代表大会，本次 会议的召集、召开和表决程序符合职工代表大会的相关规定。 经职工代表大会审议通过，选举高佑成先生（简历见附件）为公司职工代 表董事，任期自本次职工代表大会通过之日起至公司第五届董事会任期届满之 日止。 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-078 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 高佑成先生的任职资格符合相关法律法规、行政法规、规范性文件对董事 任职资格的要求，不存在《公司法》《上海证券交易所股票上市规则》及《公 司章程》等规定的不得担任公司董事的情形，不属于失信被执行人，未受到过 中国证监会及其他有关部门的处罚 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-079 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于公司高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 益丰大药房连锁股份有限公司（以下简称"公司"）董事会于近日收到公司副 总裁章佳先生的书面辞职报告。章佳先生因个人原因申请辞去公司副总裁职务， 辞职后不再担任公司其他任何职务。 一、高级管理人员离任情况 (一) 提前离任的基本情况 | 姓名 | 离任职 | | | 原定任期 | 离任 | 是否继续在上 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 务 | 离任时间 | | 到期日 | 原因 | 市公司及其控 股子公司任职 | （如适 用） | 毕的公开 | | | | | | | | | | 承诺 | | 章 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-077 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 8 月 25 日 (二)股东会召开的地点：湖南省长沙市金洲大道 68 号益丰医药物流园三楼 本次会议采取现场投票和网络投票相结合的方式召开，公司董事会召集本次 会议，董事长高毅先生主持。本次会议的召集、召开和表决方式符合《公司法》 《上海证券交易所股票上市规则》《公司章程》和公司《股东大会议事规则》的 规定，合法有效。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、公司在任监事3人，出席3人； 3、董事会秘书范炜出席会议；公司部分其他高管列席本次会议。 二、 议案审议情况 (一)非累积投票议 ...

关于益丰大药房连锁股份有限公司 2025年第二次临时股东会的 法律意见书 二O二五年八月 致：益丰大药房连锁股份有限公司 湖南启元律师事务所（以下简称"本所"）接受益丰大药房连锁股份有限公 司（以下简称"公司"）的委托，指派本律师出席了公司 2025 年第二次临时股东 会（以下简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人 员及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发 表本法律意见。 本律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股东会规则》（以下简称"《股东会规则》"） 等我国现行法律、法规、规范性文件以及《益丰大药房连锁股份有限公司章程》 （以下简称"《公司章程》"）的有关规定出具本法律意见书。 本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚 ...

Core Viewpoint - Yifeng Pharmacy announced the resignation of Vice President Zhang Jia due to personal reasons, effective immediately upon delivery of the resignation letter to the board [1] Company Summary - The board of directors received a written resignation report from Vice President Zhang Jia on August 25 [1] - Zhang Jia will not hold any other positions within the company after resigning [1]

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

Group 1 - A-shares have shown a significant upward trend since August, with foreign institutions accelerating their investments in the market [1] - As of August 21, foreign institutions held approximately 2.5 trillion yuan in A-shares, an 8% increase from the end of 2024, representing 2.72% of the total circulating market value [1] - 920 companies have disclosed their mid-year reports for 2025, with 261 companies having QFII as a major shareholder, collectively holding about 30.14 billion yuan [1] Group 2 - Foreign institutions have conducted 5,620 research visits to A-share companies this year, with major focus on sectors like machinery, pharmaceuticals, and electronics [2] - High interest in specific sub-sectors such as automation equipment, robotics, lithium batteries, and photovoltaic equipment has been noted [2] - Goldman Sachs indicates that while interest in Chinese stocks is increasing, the allocation remains conservative, suggesting potential for further market growth [2] Group 3 - Several factors are supporting the sustained market enthusiasm, including low financing balance relative to market value and strong growth in bank deposits [3] - Morgan Stanley expects a strong trend of increased capital allocation to the Chinese stock market, with attractive valuations compared to other markets [3] - The "anti-involution" policy is anticipated to enhance the investability of A-shares, with potential profit increases projected for related industries by 53% by 2027 [4]

Core Viewpoint - The company, Yaoyigou, faces severe challenges amid industry transformation, with its B2B e-commerce business being squeezed by the "unified procurement and distribution" policy and intensified competition from both traditional and internet giants in the outpatient market [2][3]. Financial Performance - In the first half of 2025, the company's revenue declined by 3.06% year-on-year to 2.157 billion yuan, and the net profit turned into a loss of 7.6144 million yuan, a year-on-year decrease of 162.95% [3][12]. - The company's revenue growth has been consistently weak since its IPO, with growth rates decreasing from 21.87% in 2021 to -1.12% in 2024, entering a negative growth phase [3][5]. - The first quarter of 2025 showed a profit of 4.1837 million yuan, but the second quarter saw a sharp loss exceeding 11.79 million yuan, indicating increased operational pressure [3]. Business Segments - The TOB business remains the main revenue source, accounting for over 97% of total revenue, with B2B e-commerce revenue down 15.61% to 1.441 billion yuan and other terminal sales down 36.20% to 489 million yuan [5][7]. - Digital distribution showed growth, increasing by 23.52% to 2.349 billion yuan, but overall TOB business still declined by 2.22% [5][7]. - The TOC business, while showing a significant increase in online retail revenue (up 225.87% to 56.97 million yuan), still contributed minimally to overall performance due to its small revenue share [5][7]. Market Challenges - The company is experiencing a "growth without revenue" dilemma, where key performance indicators in e-commerce have improved, yet total revenue has decreased by 5.89% [9][10]. - The increase in new users is primarily from small-scale customers with low transaction values, which, combined with price compression from procurement policies, hampers the realization of scale effects [10]. - The company is under pressure from both national policies and local competition, reflecting a broader industry shift from traditional distribution models to specialized service providers [10]. Cost Structure - The company's operating loss is exacerbated by rising costs, with sales expenses increasing by 46.25% to 164 million yuan, management expenses up 6.94% to 34.48 million yuan, and financial expenses rising by 12.72% [12]. - Research and development expenses have decreased significantly, down 39.73% to 5.619 million yuan, indicating a lack of effective implementation of its R&D strategy [12]. Stock Performance - Since its IPO, the company's stock price has been on a downward trend, with a cumulative decline of 79.79% from its peak of 150 yuan, resulting in a market capitalization loss of over 10 billion yuan [11].